Drug intelligence / Profile preview

YUQ-A1007

Development stage: Phase 1
Lead developer: AllianThera Biopharma
Modality: Small Molecules
Administration: Oral

Overview

YUQ-A1007 is a novel, orally administered, gut-enriched small molecule agonist of the aryl hydrocarbon receptor (AhR). It is being developed as an anti-inflammatory agent with the primary indication for inflammatory bowel diseases (IBD). Preclinical pharmacology studies suggest that activation of AhR by this compound may modulate immune responses in the gut and offer therapeutic benefit in IBD. The drug has not yet been evaluated in human clinical studies; a first-in-human Phase 1 trial is underway to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. The originator and developer is AllianThera Biopharma[1][2][3][4][5][8].

Other names: YUQ-A1007YUQ-A-1007YUQ-A 1007YUQA-1007YUQA1007YUQA 1007

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on YUQ-A1007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YUQ-A1007.

Explore the full profile